Tecentriq (atezolizumab) - Roche
Tecentriq: "Tecentriq + nab-paclitaxel was well tolerated, with no cumulative toxicities and no new or late-onset safety signals"; Metastatic triple negative breast cancer (Roche) - Jun 4, 2019 - ASCO 2019: "Although not formally testable due to the pre-specified statistical analysis plan, updated median OS improvement from 18 to 25 months was observed in the PD-L1+ population (HR 0.71)" 
P3 data
Jun 4, 2019